| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/02/2022 | 562.87% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 05/05/2022 | 98.86% | Piper Sandler | $25 → $1.5 | Downgrades | Overweight → Neutral |
| 05/04/2022 | 1093.16% | SVB Leerink | $22 → $9 | Maintains | Outperform |
| 01/06/2022 | 2816.61% | SVB Leerink | $32 → $22 | Maintains | Outperform |
| 07/02/2021 | 3479.48% | CICC | → $27 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 3479.48% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 04/13/2021 | 4142.34% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
Connect Biopharma Hldgs Questions & Answers
The latest price target for Connect Biopharma Hldgs (NASDAQ: CNTB) was reported by Cantor Fitzgerald on June 2, 2022. The analyst firm set a price target for $5.00 expecting CNTB to rise to within 12 months (a possible 562.87% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ: CNTB) was provided by Cantor Fitzgerald, and Connect Biopharma Hldgs initiated their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on June 2, 2022 so you should expect the next rating to be made available sometime around June 2, 2023.
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a initiated with a price target of $0.00 to $5.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.75, which is within the analyst's predicted range.